目的探讨米非司酮联合米索前列醇用于中期妊娠引产的临床效果以及安全性。方法选取2009年1月到2011年2月我院收治的要求终止妊娠的患者100例,随机分为对照组与观察组,每组50例。对照组给予利凡诺羊膜腔内注射引产;观察组给予米非司酮联合米索前列醇引产。比较两组患者从宫缩开始到引产结束时间、引产时间、引产成功率、出血量、清宫率以及并发症等指标。结果观察组从宫缩开始到引产结束以及引产时间均明显低于对照组;观察组48h引产率明显高于对照组,出血量和清宫率明显少于对照组(P<0.05);两组并发症比较差异无统计学意义(P>0.05)。结论米非司酮联合米索前列醇用于中期妊娠引产的疗效确切,安全可靠,值得推广应用。 Objective To investigate the clinical efficacy and safety of mifepristone combined with misoprostol in induction of labor during mid-term pregnancy. Methods From January 2009 to February 2011, 100 cases of patients requiring termination of pregnancy in our hospital were randomly divided into control group and observation group, with 50 cases in each group. The control group was given rivanol intramuscular injection of induced abortion; the observation group was given mifepristone combined with misoprostol. Comparing the two groups of patients from the beginning of contractions to the end of induction of labor, the time of induction of labor, the success rate of induced labor, the amount of bleeding, clearance rate and complications and other indicators. Results The observation group from the beginning of contractions to the end of induction of labor and induction of labor time were significantly lower than the control group; 48h induction group was significantly higher than the control group, the amount of bleeding and curettage significantly less than the control group (P <0.05) The difference was not statistically significant (P> 0.05). Conclusion Mifepristone combined with misoprostol for induction of labor in the second trimester of pregnancy is effective, safe and reliable, it is worth to promote the application.